Details for Patent: 8,921,377
✉ Email this page to a colleague
Which drugs does patent 8,921,377 protect, and when does it expire?
Patent 8,921,377 protects VERQUVO and is included in one NDA.
This patent has eighty-seven patent family members in forty-six countries.
Drugs Protected by US Patent 8,921,377
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-001 | Jan 19, 2021 | RX | Yes | No | 8,921,377 | ⤷ Subscribe | REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45% | ⤷ Subscribe | ||||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-002 | Jan 19, 2021 | RX | Yes | No | 8,921,377 | ⤷ Subscribe | REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45% | ⤷ Subscribe | ||||
| Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-003 | Jan 19, 2021 | RX | Yes | Yes | 8,921,377 | ⤷ Subscribe | REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45% | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,921,377
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2576547 | ⤷ Subscribe | PA2021518 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2576547 | ⤷ Subscribe | CA 2021 00032 | Denmark | ⤷ Subscribe |
| European Patent Office | 2576547 | ⤷ Subscribe | LUC00221 | Luxembourg | ⤷ Subscribe |
| European Patent Office | 2576547 | ⤷ Subscribe | 122021000048 | Germany | ⤷ Subscribe |
| European Patent Office | 2576547 | ⤷ Subscribe | 301146 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2576547 | ⤷ Subscribe | 2021C/553 | Belgium | ⤷ Subscribe |
| European Patent Office | 2576547 | ⤷ Subscribe | C02576547/01 | Switzerland | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
